Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?Think of last pt who died of mCRC: No. lines of Tx received? Did that pt receive regorafenib?Think back to the last patient in your practice who died of mCRC: How many lines of therapy did that patient receive? Did that patient receive regorafenib at some point during his or her course of metastatic disease? Foubert F et al. Options for metastatic colorectal cancer beyond the second line of treatment. Dig Liver Dis 2013;[Epub ahead of print]. Abstract Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: Aflibercept and regorafenib. J Gastrointest Oncol 2013;4(2):231-8. Abstract Saltz L. Systemic therapy for metastatic colorectal cancer. J Natl Compr Canc Netw 2013;11(5 Suppl):649-52;Abstract. Smaglo BG, Hwang J. Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. J Gastrointest Oncol 2013;4(3):299-307. Abstract Troiani T et al. Beyond bevacizumab: New anti-VEGF strategies in colorectal cancer. Expert Opin Investig Drugs 2012;21(7):949-59. Abstract |